Stocksigma LogoStocksigma Logo

ChrysCapital-Backed Novartis India Outlines Strategy to Double Revenue in 4–5 Years

Following ChrysCapital's acquisition of a 70.68% stake, Novartis India is executing a commercial reset to double its annualized ~INR 650 crore revenue run

ChrysCapital-Backed Novartis India Outlines Strategy to Double Revenue in 4–5 Years

Novartis India Ltd · Transcript · 15 Sept 2026, 9:29 pm

ChrysCapital-Backed Novartis India Outlines Strategy to Double Revenue in 4–5 Years Following ChrysCapital's acquisition of a 70.68% stake, Novartis India is executing a commercial reset to double its annualized ~INR 650 crore revenue run rate over the next four to five years. Growth will be driven by direct marketing across six anchor therapies, expanding C&F points from 4 to 25, and deploying ~900 MRs. Recent moves include acquiring Pfizer’s Minipress XL (INR 228 crore MAT revenue) for INR 1,250 crore and in-licensing ophthalmology brands. Upfront quarterly investments of INR 40–50 crore will compress near-term margins before recovering to >20% within 2–3 years.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements